News

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

09-12-2014

US biotech giant Amgen saw its shares rise 1.9% to $172.00 yesterday after the top US patent appeal court…

AmgenAnti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiosimilarsCubicinCubist PharmaceuticalsEnbrelGenericsHospiraLegalNovartisPatentsSandozUSA

Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA

Micreos' Staphefekt is the world's first bacteria-killing enzyme for human use in MRSA

07-11-2014

The breakthrough achieved by Dutch bacterial specialist Micreos is the most promising development the…

Antibiotics and Infectious diseasesBiosimilarsBiotechnologyInterviewsMicreosNetherlandsResearchStaphefekt

Back to top